Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Metabolic associated fatty liver disease (MAFLD) is the most common and harmful chronic liver
disease, and it is increasingly diagnosed in many developed and developing countries.
Previous studies suggested a significant association between hyperuricemia and MAFLD and that
hyperuricemia plays a causal role in the development of MAFLD.
Xanthine oxidase is a key enzyme in uric acid metabolism, and It thus can be considered as is
a therapeutic target for MAFLD, so long-term urate-lowering therapy may play a role in
amelioration of MAFLD by controlling uric acid levels. So, this study is conducted to assess
the effect of controlling hyperuricemia using different xanthine oxidase inhibitors on
amelioration of MAFLD.